QBIO
Q BioMed Inc. (OTCMKTS:QBIO) is another roller coaster in play on the OTC. This is an interesting player in the small float small-cap biotech growth space that has projects in motion to attack a major growth market (non-verbal learning disorder) with little competition and big potential. And the chart is screaming that smart traders and investors should do some due diligence here – which is why we put in front of you today.
The company just announced that its technology research partner Mannin Research Inc. presented positive data on a potential new treatment for acute kidney injury (AKI).
According to the release, “The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC. In the US alone, the cost of hospitalizations for patients with complications arising from AKI can range between $5.4 and $24.0 billion1. There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the US2. Current treatments for AKI are mainly supportive and do not treat the underlying condition.”
Read More at: dailytrendingstocks....otc-alpp-qbio-lgorf/